GlassScriptPhysician profile
Arvind Neelakantan
NPI 1205889052
$90,133.24
in general payments reported to CMS, 2019-2025
22 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $15K · 2021: $21K · 2022: $15K · 2023: $1,438 · 2024: $564 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,943.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $44,364.23 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23,980.52 | 2019-2021 | |
| Alcon Vision LLC | $7,754.01 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $7,644.51 | 2022-2025 | Vyzulta, Lotemax Sm, Xiidra |
| Allergan, INC. | $1,675.06 | 2019-2022 | |
| Abbvie INC. | $1,453.12 | 2022-2025 | |
| Glaukos Corporation | $1,172.26 | 2019-2025 | Idosetr, Istent Infinite, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $406.63 | 2019-2021 | |
| Sight Sciences, INC. | $242.39 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec USA, INC. | $226.80 | 2021-2023 | Clarus |
| Nova Eye, INC. | $206.15 | 2023 | |
| Ellexiscience | $185.73 | 2019 | |
| Ivantis, INC | $162.30 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $152.81 | 2025 | Tecnis Iol |
| Rxsight INC | $144.42 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $108.11 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $65.91 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $60.59 | 2019-2021 | |
| Thea Pharma INC. | $57.33 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $35.79 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $17.32 | 2021 | |
| Iridex Corporation | $17.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Neelakantan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.